IL13 and colorectal carcinoma: In a model of sporadic CRC, genetic IL-13 deficiency significantly reduced tumour burden, and adoptive transfer of IL-13+ ILC2s compared to IL-13– ILC2s led to enhanced MDSC activation and downstream suppression of anti-tumoural IFNγ+ CD8+ T cells and Th1 cells [24].